Abstract: Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has emerged as a transformative therapeutic agent not only for type 2 diabetes mellitus (T2DM) and obesity but also for cardiovascular diseases (CVD). This review synthesizes current literature on semaglutide's cardiovascular benefits, highlighting its efficacy in reducing major adverse cardiovascular events (MACE), lowering blood pressure, and improving outcomes in heart failure with preserved ejection fraction (HFpEF). The molecular mechanisms, structure-activity relationships, current clinical limitations, and future perspectives of semaglutide in cardiovascular medicine are discussed, demonstrating its potential to modify the natural history of atherosclerosis and cardiovascular risk across diverse patient populations.
1. Introduction
Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality, particularly among patients with type 2 diabetes mellitus (T2DM) and obesity [1]. The advent of glucagon-like peptide-1 receptor agonists (GLP-1RAs) has shifted the treatment paradigm from isolated glycemic control to comprehensive cardiovascular risk reduction [1][8]. Semaglutide, available in both subcutaneous and oral formulations, has demonstrated significant cardioprotective effects in landmark cardiovascular outcome trials (CVOTs) such as SUSTAIN 6 and PIONEER 6 [1][9]. Recent evidence extends these benefits to non-diabetic populations with obesity and established CVD, positioning semaglutide as a cornerstone therapy in cardiovascular medicine and prompting updates to international clinical guidelines [3][7][9].
2. Pharmacological Activity
Semaglutide exhibits robust pharmacological activity across the cardiovascular continuum. In the SUSTAIN 6 trial, subcutaneous semaglutide significantly reduced the risk of MACE (a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) by 26% in patients with T2DM [1][3]. The PIONEER 6 trial confirmed the cardiovascular safety of oral semaglutide, showing a 49% relative risk reduction in cardiovascular death [2]. Notably, post hoc analyses indicate that these cardiovascular benefits are observed regardless of baseline metformin use, suggesting an independent cardioprotective effect [9].
Beyond T2DM, the SELECT trial demonstrated a 20% reduction in MACE among overweight or obese adults with pre-existing CVD but without diabetes [5][7]. Semaglutide also effectively lowers systolic blood pressure, with significant reductions observed even in hypertensive cohorts [11]. Furthermore, the STEP-HFpEF trials revealed that semaglutide significantly improves heart failure-related symptoms, physical limitations, and exercise tolerance in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) [4][6][12].
3. Molecular Mechanism of Action
The anti-atherogenic and cardioprotective mechanisms of semaglutide are multifaceted. GLP-1 receptors are expressed throughout the cardiovascular system, including in endothelial cells, smooth muscle cells, and cardiomyocytes [1]. Semaglutide promotes arterial vasodilation by stimulating nitric oxide (NO) release and reduces intracellular reactive oxygen species (ROS), thereby preventing oxidative stress injury [1].
At the vascular level, it actively inhibits macrophage foam cell formation, attenuating the development of atherosclerotic plaques [1]. Semaglutide also exerts potent anti-inflammatory effects, evidenced by clinically meaningful reductions in systemic inflammatory markers such as C-reactive protein (CRP), TNF-α, and IFN-γ [1][4]. Additionally, it improves the lipid profile by inhibiting postprandial increases in triglycerides and free fatty acids, and reducing total cholesterol, low-density lipoprotein (LDL), and very-low-density lipoprotein (VLDL) levels [1].
4. Structure-Activity Relationship (SAR)
Semaglutide is a long-acting analogue of human GLP-1, sharing 94% structural homology with the native peptide [6]. Native GLP-1 has a very short half-life (approximately 2 minutes) due to rapid enzymatic degradation. To overcome this, semaglutide was structurally modified by adding a hydrophilic spacer and a fatty acid side chain [6]. These modifications facilitate reversible binding to serum albumin, shielding the molecule from degradation and significantly prolonging its half-life to enable convenient once-weekly subcutaneous administration [6].
For the oral formulation, semaglutide is co-formulated with the permeation enhancer sodium N-[8-(2-hydroxybenzoyl)amino] caprylate (SNAC). SNAC protects the peptide from enzymatic degradation in the stomach and facilitates its transcellular absorption across the gastric mucosa, achieving suitable systemic bioavailability for once-daily oral dosing [1].
5. Current Limitations
Despite its profound benefits, semaglutide therapy is associated with several limitations. The most common adverse events are gastrointestinal (GI), including nausea, vomiting, diarrhea, and constipation [6][7]. These GI effects arise from both peripheral mechanisms (delayed gastric emptying) and central activation of GLP-1 receptors in the brainstem's vomiting centers, such as the area postrema [6].
Other safety concerns include a slightly increased risk of gallbladder-related disorders (such as cholelithiasis) and acute pancreatitis [6][7]. Furthermore, while oral semaglutide demonstrated cardiovascular safety in PIONEER 6, the trial was event-driven and underpowered to definitively prove superiority over placebo for MACE reduction, necessitating larger, longer-term studies [2]. Finally, the high cost, accessibility issues, and the need for careful dose titration to manage tolerability remain significant barriers to widespread clinical use [6][9].
6. Future Perspectives
The future of semaglutide in cardiovascular medicine is highly promising. Ongoing large-scale trials, such as the SOUL study, aim to definitively establish the cardiovascular superiority of oral semaglutide over a longer follow-up period [1]. The SELECT-LIFE observational study will evaluate the long-term (up to 10 years) cardiovascular effects in participants from the SELECT trial [3].
Research is also expanding into new populations, including patients with Type 1 Diabetes (T1DM). Trials like RESET1 and T1-DISCO are currently investigating semaglutide's impact on arterial stiffness, kidney function, and cardiometabolic risk markers in T1DM [14]. Additionally, emerging evidence from the ESSENCE trial suggests semaglutide may have disease-modifying effects in metabolic dysfunction-associated steatohepatitis (MASH), a condition closely linked to elevated cardiovascular risk [6]. Early initiation of semaglutide to modify the natural history of atherosclerosis before clinical manifestation represents a critical frontier in preventive cardiology [1].
